IL33 and asthma: Non-type-2 (neutrophilic/pauci-granulocytic) asthma would therefore appear as an orphan disease, with some drugs such as macrolides being unequally efficient (42), and new drugs being far upstream of any evidence-based interest (anti-IL-17, and drugs targeting epithelial-derived cytokines such as TSLP, IL-33 or IL-25) (43).